Houston tech company receives corporate investment, HX names new board members, and more innovation news

short stories

From new board members at Houston Exponential to startups receiving funding, here are the latest short stories of Houston innovation. Photo by Zview/Getty Images

Houston's innovation ecosystem has been booming with news, and it's likely some might have fallen through the cracks.

For this roundup of short stories within Houston innovation, a startup snags funding from a new corporate venture group, a blockchain startup gets major kudos, CTV's latest investment, and more.

HX names newest board members

HX has five more members of its board. Photo courtesy

Houston Exponential has announced five new members to its governing board. Joining the group is:

  • Stephanie Campbell, managing director of the Houston Angel Network and general partner at The Artemis Fund
  • Martha Castex-Tatum, Houston City Council member
  • Gordon Daugherty, co-founder and president of Capital Factory
  • Emily Keeton, CFO of Mercato and co-founder of Station Houston
  • Roberto Moctezuma, founder and CEO of Fractal River
The board is chaired by Barbara Burger of Chevron and Chevron Technology Ventures. She will continue on as chair until the end of next year, when Blair Garrou of Mercury Fund will take over.

New corporate venture fund makes first investment

Houston-based SmartAC emerged from stealth mode this summer. Photo courtesy of smartac.com

Pinnacle Ventures, a corporate venture fund created by Pinnacle based just outside of Houston in Pasadena, announced the company has invested in Houston-based SmartAC.com, a member-based technology platform that monitors the health of air conditioning systems.

The deal is Pinnacle Ventures' first investment and will help SmartAC.com expand their service offerings to homeowners and top-level HVAC service providers.

"We are excited to have Pinnacle Ventures invest in our company and to have Ryan Sitton, founder and CEO of Pinnacle, join our board," says Josh Teekell, founder and CEO of SmartAC.com, in a news release. "The capital provided by Pinnacle Ventures will help us accelerate the growth required to meet our customer demand, which has scaled quickly since our launch in June.

"Additionally, this capital will help us power a new residential connected service economy for a $30 billion industry while offering our service partners a way to increase loyalty through improved transparency and customer experience," Teekell continues. "We're very much aligned with Pinnacle Ventures' focus on improving reliability through innovation and are confident that this investment will help us support our end users."

Data Gumbo recognized as an innovative blockchain company

CB Insights ranked 50 blockchain companies and one Houston startup made the cut. Photo via CB Insights

CB Insights released its inaugural Blockchain 50 ranking and named Houston-based Data Gumbo among the top blockchain companies in the world.

"The Blockchain 50, which we've created in conjunction with Blockdata, was born out of a desire to reduce that uncertainty and recognize the pioneering companies using the blockchain," says CB Insights CEO Anand Sanwal in the study. "This inaugural class of the Blockchain 50 is tackling a range of use cases across trade finance, capital markets, exchanges and more and are being used by banks, governments and major retailers."

Combined, the 50 companies included in the ranking have raised over $3 billion across 113 deals since 2017.

"Being named to this CB Insights' list is an honor and testament to the power of Data Gumbo's blockchain network GumboNet," says Andrew Bruce, CEO and Founder, of Data Gumbo in a news release. "Our smart contracts enable companies to leverage blockchain technology across the global business infrastructure to capture critical cost savings and value, forging a new foundation for commercial transactions: one based on trust, transparency, speed and visibility."

Currux Vision is deploying its technology in California

The Houston company's technology has been tested in California. Photo via currux.vision

Houston-based Currux Vision, which uses infra-tech artificial intelligence and machine learning solutions for smart city infrastructure, has conducted testing with the city of San Jose, California, and its department of transportation.

According to the tests, Currux Vision's SmartCity ITS can operate at 99 percent accuracy in the city. Moreover, Currux Vision can achieve high resolution results with older legacy digital and analog camera systems that offer lower resolution. Testing included but was not limited to vehicle detection and classification, turning movement counts, pedestrian counts, bicycle discrimination, stopped vehicles, and speeding, according to a press release.

"Increasing urbanization, traffic, mode shift, and increasing focus on safety drive the urgent need for a next-generation traffic management solution like our SmartCity ITS," says Alex Colosivschi, founder and CEO of Currux Vision, in the release. "We believe that efficient mobility and being able to do more with less creates economic opportunities, enables trade, improves quality of life, and facilitates access to markets and services effectively leveraging resources. ... We are happy to have worked with a great partner like San José's Department of Transportation to prove these transportation solutions."

Chevron Technology Ventures invests in software company

Chevron Technology Ventures, led by Barbara Burger, has announced its latest investment. Courtesy of CTV

Houston-based Chevron Technology Ventures has invested in a Denver-based container platform company's latest round. Nubix today announced it has closed $2.7 million in seed financing led by Tuscan Management with strategic investment from Chevron Technology Ventures, in addition to participation from other new investors.

"Businesses worldwide are investing in digital transformation initiatives with IoT-based solutions," says Rachel Taylor, Nubix co-founder and CEO, in a news release. "Our unique innovation in container and services technology enables unprecedented agility and safety when building, deploying and managing applications at the edge.

"We're delivering on digital transformation's requirements for agile compute at the edge, empowering organizations to analyze data in real-time where the data is actually created. This is a massive market opportunity for Nubix and we look forward to working hand-in-hand with our new investors as we drive agility and intelligence to the edge."

Golden Section Ventures invests in Austin startup

GSV has invested in Accelerist's impact-driven software. Image via accelerist.com

Austin-based Accelerist Inc. raised a $1 million investment round led by Houston-based Golden Section Ventures to catalyze the company's growth plans. Accelerist specializes in social impact partnership technology that nonprofits use to prospect, screen, access and measure the efficacy of their relationships with each other.

"We are very impressed with what Brittany (Hill, CEO and founder) and her team have built and are excited to join the journey," says Dougal Cameron, General Partner at GSV. "We are confident that Accelerist can be the standard of excellence for social impact partnership technology. This solution is more needed than ever."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings